A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01678872|
Recruitment Status : Enrolling by invitation
First Posted : September 5, 2012
Last Update Posted : May 29, 2014
|Condition or disease||Intervention/treatment||Phase|
|Age-Related Macular Degeneration||Drug: RetinoStat||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||21 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Long Term Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration|
|Study Start Date :||August 2012|
|Estimated Primary Completion Date :||November 2027|
|Estimated Study Completion Date :||November 2027|
Long Term Follow up
Long Term follow up of patients who received RetinoStat in a previous study.
Long Term Follow up of patients who received RetinoStat in a previous study
- The incidence of adverse events [ Time Frame: 15 years ]The number of subjects with treatment emergent adverse events.
- The change from baseline in BCVA. [ Time Frame: 15 years ]The change from baseline in Best Corrective Visual Acuity.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01678872
|United States, Maryland|
|John Hopkins University Hospital|
|Baltimore, Maryland, United States, 21287-9277|
|United States, Oregon|
|Oregon Health & Science University|
|Portland, Oregon, United States, 97239|
|Principal Investigator:||Peter Campochiaro, MD||John Hopkins University Hospital|